Anavex Life Sciences; should we be concerned?"potential to halt and/or reverse the course of Alzheimers disease." Yikes; should we be worried? Gary. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimers disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavexs lead drug candidate, ANAVEX 2-73 is currently in a Phase 2a clinical trial for Alzheimers disease. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic potential to halt and/or reverse the course of Alzheimers diseasereceptors and successfully completed Phase 1 with a clean safety profile. Preclinical studies demonstrated its . It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation (MJFF) for Parkinsons Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinsons disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinsons disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimers hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com.